388 related articles for article (PubMed ID: 26271795)
1. Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists.
Uccellatore A; Genovese S; Dicembrini I; Mannucci E; Ceriello A
Diabetes Ther; 2015 Sep; 6(3):239-56. PubMed ID: 26271795
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
[TBL] [Abstract][Full Text] [Related]
5. GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond - New Insights 2015.
Gallwitz B
Eur Endocrinol; 2015 Apr; 11(1):21-25. PubMed ID: 29632562
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
Guyton J; Jeon M; Brooks A
Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
[TBL] [Abstract][Full Text] [Related]
7. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
[TBL] [Abstract][Full Text] [Related]
8. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus.
Harris KB; McCarty DJ
Ther Adv Endocrinol Metab; 2015 Feb; 6(1):3-18. PubMed ID: 25678952
[TBL] [Abstract][Full Text] [Related]
10. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
Meece J
Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future.
Kalra S; Baruah MP; Sahay RK; Unnikrishnan AG; Uppal S; Adetunji O
Indian J Endocrinol Metab; 2016; 20(2):254-67. PubMed ID: 27042424
[TBL] [Abstract][Full Text] [Related]
13. A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.
Kayaniyil S; Lozano-Ortega G; Bennett HA; Johnsson K; Shaunik A; Grandy S; Kartman B
Diabetes Ther; 2016 Mar; 7(1):27-43. PubMed ID: 26886440
[TBL] [Abstract][Full Text] [Related]
14. Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes.
Yabe D; Seino Y
Expert Rev Endocrinol Metab; 2014 Nov; 9(6):659-670. PubMed ID: 30736202
[TBL] [Abstract][Full Text] [Related]
15. Clinical Efficacy of Once-weekly Glucagonlike Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
Bailey TS
J Fam Pract; 2018 Jun; 67(6 suppl):S14-S24. PubMed ID: 29912997
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes.
Hinnen D
Diabetes Spectr; 2017 Aug; 30(3):202-210. PubMed ID: 28848315
[TBL] [Abstract][Full Text] [Related]
17. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis.
Li Z; Zhang Y; Quan X; Yang Z; Zeng X; Ji L; Sun F; Zhan S
PLoS One; 2016; 11(5):e0154206. PubMed ID: 27158818
[TBL] [Abstract][Full Text] [Related]
19. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs.
Rodbard HW
Diabetes Technol Ther; 2018 Jun; 20(S2):S233-S241. PubMed ID: 29870275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
